publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
Dato-DXd
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
T-DXd
Use of real-world evidence in a virtual bridging analysis for a human epidermal growth factor receptor 2-targeted antibody-drug conjugate in gastric cancer
T-DXd
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
Edoxaban
Relationship between direct oral anticoagulant doses and clinical outcomes in elderly patients with non-valvular atrial fibrillation — ANAFIE Registry sub-analysis
Edoxaban
Impact of glycated hemoglobin on 2-year clinical outcomes in elderly patients with atrial fibrillation: Sub-analysis of ANAFIE registry, a large observational study
T-DXd
Trastuzumab deruxtecan dosing in human epidermal growth factor receptor 2-positive gastric cancer: population pharmacokinetic modeling and exposure-response analysis
Edoxaban
Anticoagulant therapy and home blood pressure-associated risk for stroke/bleeding events in elderly patients with non-valvular atrial fibrillation: The sub-cohort study of ANAFIE registry
Dato-DXd
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer
Edoxaban
Causes of death in elderly patients with non-valvular atrial fibrillation - results from the ANAFIE registry
Dato-DXd
First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01